What we do

Omixon is a global biotechnology company that commercializes disruptive innovations specializing in targeted applications for Next Generation Sequencing (NGS). The Omixon Holotype HLA™ product combines a targeted HLA Assay and the Omixon HLA Twin™ software to deliver the most accurate high-resolution HLA genotyping available. Omixon maintains an active grant-funded research program and assists scientists and clinicians to analyze the most challenging genomic regions including HLA, KIR and ABO.


Omixon Blog

Join Us at EFI for Free NGS Workshops on Holotype HLA™

Contact us for more informations about our workshops Novele Allele Discovery with HLA Twin genotyping software, featuring the Traffic Light System (TLS) for efficient throughput   With 99.8% accuracy in genotyping NGS data, the Omixon Holotype HLA combined assay and software …more

By kriszta.katona 0 comments

Next-Generation Sequencing Based HLA Typing of Saliva and Blood Samples from the Same Donors Produces Concordant Typing Results

Authors: Szilveszter Juhos, György Horváth, Attila Bérces, Curt Lind, Deborah Ferriola, Anh Huynh, Larissa Slavich, Dimitri Monos, Mike Tayeb, Rafal Iwasiow Aim: We are presenting the results of next-generation sequencing (NGS) based HLA typing, using blood and saliva sources from …more

By kriszta.katona 0 comments